title: Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
abstract: OBJECTIVE
  ConstaTRE is an open-label, randomised, controlled, relapse prevention trial in patients with stable schizophrenia or schizoaffective disorder switched to risperidone long-acting injectable (RLAI) or oral quetiapine, and was designed to test the hypothesis that injectable antipsychotic treatment with risperidone would be more effective than oral therapy with quetiapine. Here we report the functional recovery results from the ConstaTRE trial.
  
  
  METHODS
  Clinically stable adults previously treated with oral risperidone, olanzapine, or oral first-generation antipsychotics were randomised to RLAI or quetiapine for 24 months. Functional recovery was assessed using the Social and Occupational Functioning Assessment Scale (SOFAS) and two quality-of-life (QoL) measures [Medical Outcomes Survey Short Form-12 (SF-12) and Schizophrenia Quality-of-Life Scale Revision 4 (SQLS-R4)].
  
  
  RESULTS
  A total of 666 patients were randomised and treated with RLAI (n = 329) or quetiapine (n = 337). Relapse occurred in 16.5% RLAI and 31.3% quetiapine patients. Significant improvements in SOFAS, SF-12, and SQLS-R4 scores were observed from baseline to month 24 with both RLAI and quetiapine. At months 6, and 12, and endpoint, improvement in SOFAS score was significantly greater for RLAI than quetiapine (p < 0.05).
  
  
  CONCLUSIONS
  Among patients with stable schizophrenia or schizoaffective disorder, the likelihood of functional recovery appears to be higher in those switching to RLAI than to quetiapine, although improvements in functional status and QoL were observed with both treatments.
authors.affiliation: 1 Department of Adult Psychiatry and INSERM Center 894, Sainte Anne Hospital University of Paris Descartes, Paris, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Rouillon
authors.affiliation: 2 Department of Forensic Psychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden.
authors.forename: Lars
authors.initials: L
authors.lastname: Eriksson
authors.affiliation: 3 Psychiatry Department, Kaunas University of Medicine, Kaunas, Lithuania.
authors.forename: Benjaminas
authors.initials: B
authors.lastname: Burba
authors.affiliation: 4 Psychiatric Department, 1st Medical School, General University Hospital and Charles University, Prague, Czech Republic.
authors.forename: Jiri
authors.initials: J
authors.lastname: Raboch
authors.affiliation: 5 Third Department of Psychiatry, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Georgios
authors.initials: G
authors.lastname: Kaprinis
authors.affiliation: 6 Medical Affairs EMEA, Janssen-Cilag GmbH, Neuss, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Schreiner